To examine the antitumor efficacy of the combination therapy of pyrotinib plus chrysin against HER2-positive breast cancer, BT-474 and SK-BR-3 cells were treated with chrysin-only, pyrotinib-only or combination treatment of chrysin with pyrotinib. Here, ERBB2 is linked to breast carcinoma.